Testosterone Pellets

Testosterone pellets are subcutaneous testosterone implants, one of the delivery routes available for testosterone replacement therapy alongside oral, transdermal, intramuscular, and other subcutaneous formulations. ^{[1] [2]} Fused crystalline testosterone pellets were approved in the USA by the FDA in 1972 but were not marketed until 2008, and the current formulation is Testopel. ^[3] The main established indication for testosterone replacement therapy is androgen deficiency (hypogonadism), the goal being to replace testosterone at levels as close to physiological as possible. ^{[4] [3]} A long-acting formulation is appealing to patients and physicians because of the short half-life of testosterone, and pellets avoid the daily applications and risk of testosterone transfer to partners and family associated with topical gels. ^[3]

Continuous-release subcutaneous testosterone implants deliver stable physiologic levels of testosterone for 3 to 6 months depending on the dose implanted. ^{[4] [5] [6]} For some androgen-dependent functions testosterone acts as a pro-hormone, peripherally converted to 5-alpha-dihydrotestosterone (DHT) by 5-alpha-reductase and to 17-beta-estradiol (E2) by aromatase. ^{[4] [6]} Pellets provide a consistent substrate that allows tissues to produce DHT and E2 on demand according to local enzyme activity, without the peaks and troughs associated with gels, injections, or oral formulations. ^[6] By contrast, the mainstay parenteral testosterone esters such as enanthate and cypionate given every 2 to 3 weeks produce strongly fluctuating plasma testosterone that is not in the physiological range at least 50% of the time. ^[4]

Subcutaneous testosterone pellets are an established delivery option for testosterone replacement in hypogonadism, though a review notes their use is not widespread. ^{[5] [3]} In women, subcutaneous testosterone pellets are used off-label, since current guidelines restrict testosterone use to hypoactive sexual desire disorder with transdermal formulations. ^[7] In a narrative review of pellets in women, the only randomized controlled trial showed improved sexual activity, orgasm, and satisfaction at 24 weeks with testosterone plus estradiol implants, while other benefits derive from non-randomized observational cohorts. ^[7] An intracrinology-based review concluded that pellet therapy is promising for individualized hormone optimization with acceptable safety in monitored patients but requires validation through large-scale randomized controlled trials. ^[6] A case report described a 54-year-old man whose osteoporosis was reversed over a year on pelleted testosterone therapy, with consistent levels of 943 ng/dL and improvements in quality of life and sleep apnea, an outcome the author states should be further studied. ^[8]

In women, pellets provide sustained release over four to six months but with supraphysiologic early peaks exceeding 100 to 250 ng/dL and wide interindividual variability. ^[7] Safety data from practice-based registries in women indicated mild androgenic events such as acne and hair growth and rare transient voice changes, while cardiovascular, metabolic, and endometrial data remain sparse and inconsistent. ^[7] With increasing age the risk of adverse effects on the prostate, the cardiovascular system, and erythropoiesis increases, so short-acting testosterone preparations are considered better suited for aging androgen-deficient men. ^[4] Reported benefits of pellets for sexual function and well-being in women are hypothesis-generating and safety cannot be confirmed, so pellet use should remain individualized, off-label, and accompanied by structured monitoring rather than routine adoption. ^[7]